Core Insights - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security of China have jointly issued the new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025), which includes the long-acting growth hormone, Yipeisheng, developed by Tebao Biologics [1] - Approximately 7 million children in China suffer from growth hormone deficiency, and the number of cases is on the rise, highlighting the critical need for effective treatment options [1] - The inclusion of Yipeisheng in the new drug list is expected to alleviate the challenges faced in the pediatric growth hormone treatment sector, such as adherence issues with daily injections of short-acting formulations and the high cost and limited options of long-acting drugs [1] - The new drug list will take effect on January 1, 2026 [1] Pricing and Accessibility - Following its inclusion in the new drug list, the price of Yipeisheng will decrease by over 50%, significantly reducing the financial burden on patients and improving treatment accessibility [2]

Core Viewpoint - The announcement by Fuhong Hanlin (02696) indicates that its drug, Fuzhuoning® (Acalabrutinib), has been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025) under Category B, specifically for use in HR-positive, HER2-negative recurrent or metastatic breast cancer patients who have progressed after endocrine therapy [1] Group 1 - Fuzhuoning® is an innovative CDK4/6 small molecule inhibitor licensed by the company [1] - The drug was approved for marketing in China in May 2025, with its first indication being in combination with Fulvestrant for HR-positive, HER2-negative recurrent or metastatic breast cancer patients who have progressed after endocrine therapy [1] - In September 2025, Fuzhuoning® received an additional indication for use in HR-positive, HER2-negative locally advanced or metastatic breast cancer adult patients, in combination with aromatase inhibitors as initial endocrine therapy [1] Group 2 - The new National Medical Insurance Drug List will officially take effect on January 1, 2026 [1]

Core Viewpoint - The announcement by Fuhong Hanlin (02696) regarding the inclusion of Fuzhuoning (Apatinib) in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025) is a significant development for the company and the treatment of specific breast cancer patients [1] Group 1 - Fuzhuoning has been included in the Class B category of the National Medical Insurance Drug List for 2025, specifically for use in HR-positive, HER2-negative recurrent or metastatic breast cancer patients who have progressed after endocrine therapy [1] - The new National Medical Insurance Drug List will be officially implemented on January 1, 2026 [1] - Fuzhuoning is an innovative CDK4/6 small molecule inhibitor that was approved for marketing in China in May 2025 [1] Group 2 - The initial approved indication for Fuzhuoning is in combination with Fulvestrant for HR-positive, HER2-negative recurrent or metastatic breast cancer patients who have previously received endocrine therapy [1] - In September 2025, Fuzhuoning received an additional indication for use in HR-positive, HER2-negative locally advanced or metastatic breast cancer adult patients, in combination with aromatase inhibitors as initial endocrine therapy [1]

Core Viewpoint - The inclusion of Fuhong Hanlin's drug, Fuzhuoning (Acalabrutinib), in the National Medical Insurance Drug List for 2025 signifies recognition of its clinical value and benefits for patients, enhancing accessibility for HR-positive, HER2-negative breast cancer patients and facilitating market promotion and sales strategies [1][2]. Group 1 - Fuzhuoning has been included in the National Medical Insurance Drug List under Category B, effective January 1, 2026, for use in combination with Fulvestrant for adult patients with HR-positive, HER2-negative recurrent or metastatic breast cancer who have progressed after endocrine therapy [1] - The drug was approved for marketing in China in May 2025, initially for the same indication, and received an additional indication in September 2025 for use in combination with aromatase inhibitors as initial endocrine therapy for adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer [1] Group 2 - The recognition by the National Medical Security Administration reflects the drug's clinical value, patient benefits, and innovation level, which will improve accessibility for patients and support the drug's market promotion and sales layout [2]

复妥宁®系公司许可引进的创新型CDK4/6小分子抑制剂。2025年5月，于中国境内获批上市，首次获批 适应症为联合氟维司群用于既往接受内分泌治疗后出现疾病进展的激素受体(HR)阳性、人表皮生长因 子受体2(HER2)阴性的复发或转移性成年乳腺癌患者;2025年9月，复妥宁®于中国境内新增获批一项适 应症，用于激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性局部晚期或转移性乳腺癌成人患者： 与芳香化酶抑制剂联合使用作为初始内分泌治疗。 智通财经APP讯，复宏汉霖(02696)发布公告，近日，复妥宁®(枸橼酸伏维西利胶囊)获纳入《国家基本 医疗保险、生育保险和工伤保险药品目录(2025年 )》乙类范围，获纳入的适应症为联合氟维司群用于既 往接受内分泌治疗后出现疾病进展的激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性的复发或转 移性成年乳腺癌患者。新版国家医保药品目录将于2026年1月1日起正式实施。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 自願公告 複妥寧® （枸櫞酸伏維西利膠囊）獲納入國家醫保藥品目錄 A. 緒言 本公告由上海復宏漢霖生物技術股份有限公司（「本公司」）自願作出，以告知 本公司股東及潛在投資者本公司最新業務更新。 B. 關於複妥寧® 複妥寧®係本公司許可引進的創新型CDK4/6小分子抑制劑。2025年5月，於 中國境內獲批上市，首次獲批適應症為聯合氟維司群用於既往接受內分泌治 療後出現疾病進展的激素受體(HR)陽性、人表皮生長因子受體2(HER2)陰性 的複發或轉移性成年乳腺癌患者；2025年9月，複妥寧®於中國境內新增獲批 一項適應症，用於激素受體(HR)陽性、人表皮生長因子受體2(HER2)陰性局 部晚期或轉移性乳腺癌成人患者：與芳香化酶抑制劑聯合使用作為初始 ...

Core Viewpoint - Haichuang Pharmaceutical (688302.SH) announced that its self-developed drug, Deuteroenzalutamide soft capsule, has been included in the National Medical Insurance Drug List after negotiations, effective from January 1, 2026 [1] Group 1 - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security published the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List for 2025 [1] - Deuteroenzalutamide soft capsule is a first-class new drug developed by the company for the treatment of metastatic castration-resistant prostate cancer (mCRPC) [1] - The drug is a second-generation androgen receptor (AR) inhibitor and has received support from the National Major New Drug Creation Science and Technology Major Project [1]